Contemporary Prostate Cancer Prevalence among T1c Biopsy-Referred Men with a Prostate-Specific Antigen Level ≤ 4.0 ng per Milliliter

ObjectiveTo investigate the prostate cancer (PCa) prevalence and risk factors of men with prostate-specific antigen (PSA) level ≤ 4.0 ng/ml and an unsuspicious digital rectal examination (DRE) in a large biopsy referral cohort.Materials and methodsBetween 1997 and 2005, 855 men underwent initial transrectal ultrasound (TRUS)-guided prostate biopsy at the University Hospital Hamburg-Eppendorf. Patients with any previous surgical or medical treatment were excluded from analyses. Logistic regression analyses were performed to determine risk factors of PCa at biopsy and high-grade PCa defined as biopsy Gleason sum ≥ 7.ResultsOverall PCa detection rate was 23.1%. The majority had a biopsy Gleason sum of 6 (79.5%) and 20.5% had a biopsy Gleason sum ≥ 7. Total PSA (tPSA) and percentage of free PSA (%fPSA) were statistically significantly different in men with and without PCa (all p < 0.001). In tPSA strata ≤ 0.5, 0.6–1.0, 1.1–2.0, 2.1–3.0, and 3.1–4.0 ng/ml, PCa prevalence was 4.0%, 10.6%, 14.8%, 24.5%, and 32.1%, respectively. In logistic regression analyses addressing PCa and Gleason sum ≥ 7 at biopsy, %fPSA and prostate volume represented independent and most informative risk factors.ConclusionOur data demonstrate that a substantial percentage (23.1%) of men with a PSA ≤ 4.0 ng/ml and an unsuspicious DRE in a biopsy referral population harbor PCa, with 20.5% being high grade. Low %fPSA and low prostate volume represent important parameters in PCa and in high grade disease detection at biopsy, respectively.